Jupiter Endovascular, which is a startup spun out of Neptune Medical a year ago, raised more than its target of $40 million in series B fundraising it plans to use to further develop and launch its TFX catheter platform.
The platform, which is part of the company’s Vertex system, is designed to allow practitioners to treat areas in the human body that are not safely or easily reached using more conventional endovascular systems, the company said in an Oct. 7 press release.
The FDA in September gave the Vertex Catheter system that incorporates the TFX platform 510(k) clearance that allows devicemakers to legally market medium-risk devices in the U.S. Jupiter is slotted to present results of its first-in-human trial of the system at the upcoming Transcatheter Cardiovascular Therapeutics Conference in San Francisco.
“We’re energized by the support of this distinguished syndicate of investors as we tackle one of the greatest unmet needs in transcatheter interventions—the lack of stability and control physicians face while operating in complex cardiovascular anatomies—starting with pulmonary embolism,” Carl St. Bernard, Jupiter’s chief executive, said in the release.
Although the $40 million goal was surpassed, the company did not release the final amount raised in the latest round led by Sonder Capital. Also participating were Senvest Management, LB Investment and an unnamed corporate investor.
Jupiter was formed in August 2024 with $21 million in seed money that came from $97 million in series D venture capital funds raised by Neptune Medical. The goal, the company said, was for Jupiter to focus on improving the precision and control of catheter-based therapies, starting with treating blood clots lodged within the lung.